Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,440,000 shares, a growth of 431.1% from the November 30th total of 647,700 shares. Based on an average trading volume of 3,750,000 shares, the short-interest ratio is currently 0.9 days. Currently, 4.3% of the shares of the stock are sold short.

Institutional Trading of Chimerix

A number of hedge funds have recently modified their holdings of the business. Marshall Wace LLP purchased a new position in Chimerix during the second quarter valued at $137,000. Valeo Financial Advisors LLC increased its holdings in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 69,505 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Institutional investors own 45.42% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CMRX shares. Wedbush reaffirmed an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Wednesday, December 11th.

Chimerix Trading Down 3.6 %

NASDAQ CMRX traded down $0.12 during trading on Thursday, hitting $3.22. The company had a trading volume of 777,337 shares, compared to its average volume of 1,266,239. The company’s fifty day moving average is $1.45 and its 200-day moving average is $1.09. The company has a market cap of $289.59 million, a price-to-earnings ratio of -3.43 and a beta of 1.02. Chimerix has a one year low of $0.75 and a one year high of $3.39.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.